Anlon Healthcare IPO: GMP, Price Band, Lot Size, Allotment, Listing & More
IPO Ji brings you the most detailed coverage of Anlon Healthcare IPO including GMP today, IPO dates, price band, lot size, issue details, company financials, promoters, competitive strengths, risks, allotment process, refund and listing updates.
Anlon Healthcare IPO Highlights
- IPO Type: Book Built Issue
- IPO Open Date: August 26, 2025
- IPO Close Date: August 29, 2025
- Issue Size: ₹121.03 Crore (1.33 crore fresh equity shares)
- Price Band: ₹86 – ₹91 per share
- Face Value: ₹10 per share
- Lot Size: 164 shares per lot
- Minimum Investment (Retail): ₹14,924
- Listing Date (Tentative): September 3, 2025
- Listing Exchanges: BSE & NSE
- Lead Manager: Interactive Financial Services Ltd.
- Registrar: Kfin Technologies Ltd.
Anlon Healthcare IPO Price Band, Lot Size & Investment Details
The Anlon Healthcare IPO price band has been set between ₹86 to ₹91 per share. Investors can bid in multiples of 164 shares per lot.
Lot Size & Investment Breakdown
The minimum retail application requires ₹14,924, while high-net-worth investors (HNIs) can invest over ₹10 lakh.
Anlon Healthcare IPO Timeline (Tentative Schedule)
Anlon Healthcare Ltd
Anlon Healthcare limited is a 2013 incorporated Indian pharmaceutical chemical manufacturing company in the business of manufacturing pharmaceutical intermediates and active pharmaceutical ingredients (APIs) of high purity. The pharmaceutical industry relies on these chemicals as they become the backbone of the industry because they are used in the manufacture of life-saving drugs, nutraceuticals, veterinary medicines and personal care formulations.
Strong Business Segments
- Pharmaceutical Intermediates
- These are essential components that are utilized in the APIs manufacturing.
- Among the intermediates used by the company are Cyanoethylbenzoic Acid, Ketonitrile and Methyldesloratadine.
- The in-house production of these intermediates allows Anlon to exercise control over costs, supply, and quality to its clients.
- Active Pharmaceutical Ingredients ( (APIs)
- APIs are the most important ingredient that result into the wanted therapeutic effect by medicines.
- The APIs that Anlon Healthcare manufactures are applicable in a broad and diverse spectrum of the dosage form, including tablets, capsules, syrups, ointments, nutraceuticals products, and veterinary care medicine.
- Nets APIs are in accordance with the international standards such as IP (Indian Pharmacopeia), BP (British Pharmacopeia), EP (European Pharmacopeia), JP (Japanese Pharmacopeia) and USP (United States Pharmacopeia).
Global Presence & Regulatory Approvals
Anlon Healthcare has steadily built a global footprint, supplying its intermediates and APIs to international pharmaceutical companies. The company’s compliance with stringent quality standards has helped it secure multiple international certifications and approvals:
- 21 Drug Master Files (DMFs) filed with global regulatory agencies.
- Approvals from prestigious authorities such as:
- ANVISA – Brazil
- NMPA – China
- PMDA – Japan
- These approvals not only validate Anlon’s manufacturing quality but also open doors to export opportunities in regulated and semi-regulated markets across the globe.
Research & Manufacturing Strength
Research and innovation are central to Anlon Healthcare’s growth. The company continuously invests in R&D and process optimization to expand its product portfolio.
- 65 commercialized products already available in the market.
- 28 products at pilot stage, showing a strong pipeline for near-term commercialization.
- 49 products in laboratory testing, which indicates long-term growth potential.
- Backed by 4 state-of-the-art laboratories dedicated to testing, analysis, and product improvement.
- A strong technical workforce of 34 scientists and professionals (out of 105 total employees), including chemists, engineers, and quality analysts, ensuring strict compliance with quality, health, safety, and environmental standards.
Anlon Healthcare Financial Performance
Despite a revenue drop in FY24, the company’s profitability has improved significantly, showcasing strong cost management.
Objects of the Issue
The net proceeds from the IPO will be used for:
- ₹30.7 crore – Expansion of manufacturing plant.
- ₹43.15 crore – Working capital support.
- Debt repayment.
- General corporate purposes.
Anlon Healthcare IPO Promoters & Shareholding
Promoters of the company:
- Punitkumar R. Rasadia
- Meet Atulkumar Vachhani
- Mamata Punitkumar Rasadia
Shareholding Pattern
- Pre-Issue: 70.26%
- Post-Issue: Diluted (exact % depends on allotment).
Anlon Healthcare IPO GMP (Grey Market Premium)
- The Anlon Healthcare IPO GMP today will be updated regularly on IPO Ji.
- GMP trends are closely followed by investors to estimate expected listing gains.
Stay tuned with IPO Ji for daily Anlon Healthcare IPO GMP updates.
Anlon Healthcare IPO Allotment, Refund & Listing Updates
- Allotment Date: September 1, 2025
- Refunds Initiation: September 2, 2025
- Credit to Demat Accounts: September 2, 2025
- Listing Date: September 3, 2025 (BSE & NSE)
Frequently Asked Questions (FAQs) on Anlon Healthcare IPO
Q1. What are the subscription dates for the Anlon Healthcare IPO? The Anlon Healthcare IPO will open for subscription on Tuesday, August 26, 2025, and will close on Friday, August 29, 2025.
Q2. What is the price band of the Anlon Healthcare IPO? The price band has been fixed in the range of ₹86 to ₹91 per equity share of face value ₹10 each.
Q3. What is the minimum lot size and investment required for retail investors in the Anlon Healthcare IPO? The minimum lot size is 164 equity shares, which requires an investment of approximately ₹14,924 at the upper price band. Retail investors can apply for up to 13 lots (2,132 shares), amounting to ₹1,94,012.
Q4. When will the basis of allotment for the Anlon Healthcare IPO be finalized? The basis of allotment is expected to be finalized on Monday, September 1, 2025.
Q5. How can investors check the Anlon Healthcare IPO allotment status? Investors can check their allotment status through the website of the registrar, Kfin Technologies Ltd., or via the BSE/NSE IPO allotment portals. IPO Ji will also provide direct allotment status links once available.
Q6. When will refunds be initiated for non-allottees in the Anlon Healthcare IPO? Refunds are scheduled to be initiated on Tuesday, September 2, 2025, following the finalization of the allotment.
Q7. When will the equity shares be credited to successful applicants’ demat accounts? The shares are expected to be credited to the demat accounts of successful allottees on Tuesday, September 2, 2025.
Q8. On which stock exchanges will the Anlon Healthcare IPO be listed, and what is the tentative listing date? The equity shares of Anlon Healthcare Limited are proposed to be listed on both the BSE and NSE, with the tentative listing date fixed as Wednesday, September 3, 2025.
Q9. What is the Grey Market Premium (GMP) of the Anlon Healthcare IPO? The Anlon Healthcare IPO GMP (Grey Market Premium) will be updated regularly on IPO Ji. GMP indicates investor sentiment and the potential premium at which shares may list over the issue price.
Q10. Who are the lead manager and registrar to the Anlon Healthcare IPO?
- Book Running Lead Manager: Interactive Financial Services Ltd.
- Registrar to the Issue: Kfin Technologies Ltd.
Bookmark IPO Ji for:
- Daily GMP updates
- Allotment status links
- Refund updates
- Listing news
